中慧生物-B(02627)：中国药审中心批准MRNA RSV疫苗IND申请

智通财经05-08

智通财经APP讯，中慧生物-B(02627)发布公告，继集团于2025年11月7日获美利坚合众国食品药品监督管理局批准其于美国提交的新药临床试验申请后，国家药品监督管理局药品审评中心已批准集团自主研发的mRNA RSV疫苗候选产品的IND申请。RSV是一种导致呼吸道感染的常见病毒，尤其是在老年人和慢性病患者等易感染人群中，可能发展成细支气管炎或肺炎等严重病例。目前在中国，RSV感染的治疗仍依赖...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2633459715?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-05-08 20:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2633459715","market":"us","top_or_hot":-1,"title":"中慧生物-B(02627)：中国药审中心批准MRNA RSV疫苗IND申请","media":"智通财经","content":"<div>\n<p>智通财经APP讯，中慧生物-B(02627)发布公告，继集团于2025年11月7日获美利坚合众国食品药品监督管理局批准其于美国提交的新药临床试验申请后，国家药品监督管理局药品审评中心已批准集团自主研发的mRNA RSV疫苗候选产品的IND申请。RSV是一种导致呼吸道感染的常见病毒，尤其是在老年人和慢性病患者等易感染人群中，可能发展成细支气管炎或肺炎等严重病例。目前在中国，RSV感染的治疗仍依赖...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1439772.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>中慧生物-B(02627)：中国药审中心批准MRNA RSV疫苗IND申请</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n中慧生物-B(02627)：中国药审中心批准MRNA RSV疫苗IND申请\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-08 20:57 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1439772.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，中慧生物-B(02627)发布公告，继集团于2025年11月7日获美利坚合众国食品药品监督管理局批准其于美国提交的新药临床试验申请后，国家药品监督管理局药品审评中心已批准集团自主研发的mRNA RSV疫苗候选产品的IND申请。RSV是一种导致呼吸道感染的常见病毒，尤其是在老年人和慢性病患者等易感染人群中，可能发展成细支气管炎或肺炎等严重病例。目前在中国，RSV感染的治疗仍依赖...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1439772.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4551","symbol_name":"寇图资本持仓","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1439772.html","article_id":"2633459715","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2633459715","pubTimestamp":1778245029,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，中慧生物-B 发布公告，继集团于2025年11月7日获美利坚合众国食品药品监督管理局批准其于美国提交的新药临床试验申请后，国家药品监督管理局药品审评中心已批准集团自主研发的mRNA RSV疫苗候选产品的IND申请。目前在中国，RSV感染的治疗仍依赖广谱抗病毒药物及对症治疗。因此，迫切需要开发一种有效的RSV疫苗。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159646":"疫苗","BK4551":"寇图资本持仓","BK4501":"段永平概念","BK4532":"文艺复兴科技持仓","02627":"中慧生物-B","MRNA":"Moderna, Inc.","BK4568":"美国抗疫概念","BK4588":"碎股","IND":"Xtrackers Nifty 500 India ETF","BK4585":"ETF&股票定投概念","BK1161":"生物科技","BK4548":"巴美列捷福持仓","BK4534":"瑞士信贷持仓","BK4139":"生物科技","MRNX":"Defiance Daily Target 2X Long MRNA ETF","MRNY":"MRNA期权收益策略ETF-YieldMax","BK4533":"AQR资本管理(全球第二大对冲基金)"},"translate_title":"Zhonghui Bio-B (02627): China Center for Drug Evaluation approves IND application for MRNA RSV vaccine","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159646":1.5,"MRNY":0.6,"MRNX":0.6,"02627":1.5,"IND":1.5,"MRNA":1.5},"content_text":"智通财经APP讯，中慧生物-B(02627)发布公告，继集团于2025年11月7日获美利坚合众国食品药品监督管理局批准其于美国提交的新药临床试验申请后，国家药品监督管理局药品审评中心已批准集团自主研发的mRNA RSV疫苗候选产品的IND申请。RSV是一种导致呼吸道感染的常见病毒，尤其是在老年人和慢性病患者等易感染人群中，可能发展成细支气管炎或肺炎等严重病例。目前在中国，RSV感染的治疗仍依赖广谱抗病毒药物及对症治疗。因此，迫切需要开发一种有效的RSV疫苗。mRNA疫苗已在临床研究中显示出诱导强烈的细胞免疫反应及持久的体液免疫，使其成为保护老年人及免疫功能低下人群免受RSV引起的严重下呼吸道感染的一项具前景选择。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2633459715","isCrawlerRequest":true}